Skip to main content
Gentian Diagnostics ASA logo

Gentian Diagnostics ASA — Investor Relations & Filings

Ticker · GENT ISIN · NO0010748866 LEI · 5967007LIEEXZXHNM861 OL Manufacturing
Open in API
Filings indexed 468 across all filing types
Latest filing 2017-11-15 Report Publication Anno…
Country NO Norway
Listing OL GENT

About Gentian Diagnostics ASA

https://www.gentian.com/

Gentian Diagnostics ASA is a medical diagnostics company that develops, manufactures, and markets innovative in vitro diagnostic (IVD) reagents. The company specializes in turbidimetric immunoassays designed for open clinical chemistry platforms, aiming to enhance laboratory efficiency and support better clinical treatment decisions. Its portfolio and pipeline of diagnostic tests address biomarkers in high-impact medical areas, including kidney disease, cardiac disease, inflammation, and infection. Key products include assays for Cystatin C, NGAL, and Calprotectin. In addition to its human diagnostics portfolio, the company provides diagnostic solutions for the veterinary market. Gentian serves a global customer base through original equipment manufacturer (OEM) partners, distributors, and healthcare providers.

Recent filings

Filing Released Lang Actions
Third Quarter Financial Report
Report Publication Announcement Classification · 98% confidence The document is titled 'Third Quarter Financial Report' and explicitly states that Gentian Diagnostics AS announces its results for the third quarter. It provides key highlights and concludes with 'Please find the report for the third quarter enclosed.' Given the very short length (618 characters) and the nature of announcing results while directing the reader to an enclosed/attached report, this fits the definition of a Report Publication Announcement (RPA) rather than the comprehensive Interim/Quarterly Report (IR) itself. It is an announcement about the release of the quarterly report.
2017-11-15 English
GENTIAN DIAGNOSTICS AS RECEIVES PATENT PROTECTION FOR THE COMPANY'S TECHNOLOGY FOR MONITORING TREATMENT OF HIV INFECTIONS
Regulatory Filings Classification · 95% confidence The document is a short press release announcing that Gentian Diagnostics AS has received notification from the PCT authority that its international patent application (PCT/EP2016/067639) is patentable. It details the technology (monitoring HIV treatment via CD4 quantitation) and mentions future reporting in 'coming quarterly reports'. Since this is a specific, non-financial, non-periodic announcement about a legal/IP development (patentability), and it is not a standard regulatory filing like 10-K, ER, or IR, it best fits the general 'Regulatory Filings' category as a miscellaneous announcement, or potentially 'LTR' (Legal Proceedings Report) due to the patent focus. Given the options, 'RNS' (Regulatory Filings - general regulatory announcements and fallback) is the most appropriate classification for a press release announcing a patent milestone that doesn't fit the other specific categories like M&A, Capital Change, or Director Dealing. The document length (3735 chars) is short, but it is the primary content, not an announcement *of* another report, so RPA is not applicable.
2017-11-06 English
A new article published in CC&R is demonstrating the clinical value of plasma Calprotectin as an early biomarker of bacterial infections
Regulatory Filings Classification · 90% confidence The document is explicitly titled 'Gentian Diagnostic AS - Press Release' and discusses a newly published scientific article demonstrating the clinical value of their diagnostic test. It contains promotional and informational content typical of a press release announcing a positive development or study result. It is not a formal regulatory filing (like 10-K, AR, IR), nor is it a transcript, management discussion, or financial report. Since there is no specific category for a general press release announcing clinical/product news, and it doesn't fit the definitions for ER (Earnings Release), LTR (Legal), or CAP (Financing), the most appropriate fallback category is Regulatory Filings (RNS), which serves as a general announcement category for non-standard regulatory disclosures or significant company news releases that don't fit elsewhere.
2017-10-03 English
A new article published in CC&R is demonstrating the clinical value of plasma Calprotectin as an early biomarker of bacterial infections
Regulatory Filings Classification · 92% confidence The document is a short press release or news item announcing the publication of a scientific article in the 'Critical Care and Resuscitation (CC&R) Journal' regarding the clinical value of plasma Calprotectin as a biomarker. It details the findings, quotes the Managing Director, and provides contact information and a brief 'About' section for Gentian Diagnostics AS. It is not a formal regulatory filing (like 10-K, IR, ER), nor is it a presentation (IP) or a transcript (CT). Since it is an announcement about a specific piece of information/research that doesn't fit the other specific categories (like DIRS, DIV, CAP, etc.), the most appropriate general category is Regulatory Filings (RNS), which serves as a fallback for miscellaneous corporate announcements that are not standard financial reports or specific corporate actions.
2017-10-03 English
2nd Quarter and First Half 2017 Report
Interim / Quarterly Report Classification · 100% confidence The document is a comprehensive financial report for the second quarter and first half of 2017 for Gentian Diagnostics AS. It includes detailed financial statements (Statement of Comprehensive Income, Statement of Financial Position, Cash Flow Statement), operational highlights, management commentary on financial performance, and shareholder information. It is not a mere announcement or certification, but the actual interim financial report. Q2 2017
2017-08-23 English
2nd Quarter and First Half 2017 Report
Report Publication Announcement Classification · 98% confidence The document explicitly states it is the '2nd Quarter and First Half 2017 Report' and provides key highlights (81% revenue growth, patent filings). However, the final sentence states, 'Please find the report for the second quarter and first half year enclosed. The report will also be made available on www.gentian.no.' This structure—providing highlights and announcing the availability of the full report—strongly suggests this specific text is an announcement rather than the comprehensive report itself. Since it announces the release of a periodic financial report (Quarterly/Half-Year), the most appropriate classification based on the definitions is Report Publication Announcement (RPA). If the text contained the full financial statements, it would be classified as Interim/Quarterly Report (IR). Given the short length (737 chars) and the explicit announcement language, RPA is selected.
2017-08-23 English

Browse filings by year

11 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.